Posted by Michael Wonder on 18 Aug 2021
ICER releases draft evidence report on mavacamten for hypertrophic cardiomyopathy
18 August 2021 - Public comment period now open until 15 September 2021; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review today released a draft evidence report assessing the comparative clinical effectiveness and value of mavacamten (MyoKardia and BMS) for the treatment of hypertrophic cardiomyopathy.
